VIVOSIM LABS INC (VIVS) Fundamental Analysis & Valuation

NASDAQ:VIVS • US68620A3023

Current stock price

1.46 USD
-0.02 (-1.35%)
At close:
1.535 USD
+0.07 (+5.14%)
Pre-Market:

This VIVS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. VIVS Profitability Analysis

1.1 Basic Checks

  • VIVS had positive earnings in the past year.
  • VIVS had a negative operating cash flow in the past year.
  • VIVS had negative earnings in each of the past 5 years.
  • In the past 5 years VIVS always reported negative operating cash flow.
VIVS Yearly Net Income VS EBIT VS OCF VS FCFVIVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • VIVS's Return On Assets of -17.63% is fine compared to the rest of the industry. VIVS outperforms 76.89% of its industry peers.
  • The Return On Equity of VIVS (-27.63%) is better than 77.48% of its industry peers.
Industry RankSector Rank
ROA -17.63%
ROE -27.63%
ROIC N/A
ROA(3y)-111.01%
ROA(5y)-81.92%
ROE(3y)-181.24%
ROE(5y)-124.91%
ROIC(3y)N/A
ROIC(5y)N/A
VIVS Yearly ROA, ROE, ROICVIVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

  • The Gross Margin of VIVS (100.00%) is better than 99.81% of its industry peers.
  • VIVS's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for VIVS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.58%
VIVS Yearly Profit, Operating, Gross MarginsVIVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. VIVS Health Analysis

2.1 Basic Checks

  • VIVS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, VIVS has less shares outstanding
  • VIVS has less shares outstanding than it did 5 years ago.
  • There is no outstanding debt for VIVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VIVS Yearly Shares OutstandingVIVS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
VIVS Yearly Total Debt VS Total AssetsVIVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

  • VIVS has an Altman-Z score of -74.34. This is a bad value and indicates that VIVS is not financially healthy and even has some risk of bankruptcy.
  • VIVS has a worse Altman-Z score (-74.34) than 94.37% of its industry peers.
  • There is no outstanding debt for VIVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -74.34
ROIC/WACCN/A
WACC9.41%
VIVS Yearly LT Debt VS Equity VS FCFVIVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 2.44 indicates that VIVS has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.44, VIVS is doing worse than 72.04% of the companies in the same industry.
  • VIVS has a Quick Ratio of 2.44. This indicates that VIVS is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.44, VIVS is not doing good in the industry: 68.74% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.44
Quick Ratio 2.44
VIVS Yearly Current Assets VS Current LiabilitesVIVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. VIVS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 223.70% over the past year.
  • VIVS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.39%.
  • VIVS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -42.03% yearly.
EPS 1Y (TTM)223.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-440.49%
Revenue 1Y (TTM)16.39%
Revenue growth 3Y-54.21%
Revenue growth 5Y-42.03%
Sales Q2Q%8.33%

3.2 Future

  • The Earnings Per Share is expected to decrease by -6.30% on average over the next years.
  • VIVS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.82% yearly.
EPS Next Y2.6%
EPS Next 2Y-6.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year18.24%
Revenue Next 2Y16.82%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VIVS Yearly Revenue VS EstimatesVIVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2022 2023 2024 2025 2026 2027 1M 2M 3M 4M
VIVS Yearly EPS VS EstimatesVIVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2024 2025 2026 2027 -20 -40 -60 -80 -100

More info and screens

Find the best growth stocksShow best growing peers

4

4. VIVS Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 1.36 indicates a rather cheap valuation of VIVS.
  • Based on the Price/Earnings ratio, VIVS is valued cheaply inside the industry as 99.61% of the companies are valued more expensively.
  • VIVS is valuated cheaply when we compare the Price/Earnings ratio to 27.42, which is the current average of the S&P500 Index.
  • VIVS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 1.36
Fwd PE N/A
VIVS Price Earnings VS Forward Price EarningsVIVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIVS Per share dataVIVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3 -4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A cheap valuation may be justified as VIVS's earnings are expected to decrease with -6.30% in the coming years.
PEG (NY)0.53
PEG (5Y)N/A
EPS Next 2Y-6.3%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VIVS Dividend Analysis

5.1 Amount

  • VIVS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VIVS Fundamentals: All Metrics, Ratios and Statistics

VIVOSIM LABS INC

NASDAQ:VIVS (4/24/2026, 8:13:20 PM)

Premarket: 1.535 +0.07 (+5.14%)

1.46

-0.02 (-1.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)06-03
Inst Owners4.14%
Inst Owner Change-0.06%
Ins Owners2.78%
Ins Owner Change77.05%
Market Cap3.81M
Revenue(TTM)142.00K
Net Income(TTM)-1.23M
Analysts45.71
Price TargetN/A
Short Float %3.63%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-47.06%
Min Revenue beat(2)-49.02%
Max Revenue beat(2)-45.1%
Revenue beat(4)1
Avg Revenue beat(4)-27.06%
Min Revenue beat(4)-49.02%
Max Revenue beat(4)8.7%
Revenue beat(8)2
Avg Revenue beat(8)-27.21%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 1.36
Fwd PE N/A
P/S 26.84
P/FCF N/A
P/OCF N/A
P/B 0.86
P/tB 0.86
EV/EBITDA N/A
EPS(TTM)1.07
EY73.29%
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-4.07
FCFYN/A
OCF(TTM)-4.07
OCFYN/A
SpS0.05
BVpS1.7
TBVpS1.7
PEG (NY)0.53
PEG (5Y)N/A
Graham Number6.40034 (338.38%)
Profitability
Industry RankSector Rank
ROA -17.63%
ROE -27.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100%
FCFM N/A
ROA(3y)-111.01%
ROA(5y)-81.92%
ROE(3y)-181.24%
ROE(5y)-124.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.58%
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.44
Quick Ratio 2.44
Altman-Z -74.34
F-Score4
WACC9.41%
ROIC/WACCN/A
Cap/Depr(3y)52.61%
Cap/Depr(5y)295.14%
Cap/Sales(3y)51.89%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)223.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-440.49%
EPS Next Y2.6%
EPS Next 2Y-6.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)16.39%
Revenue growth 3Y-54.21%
Revenue growth 5Y-42.03%
Sales Q2Q%8.33%
Revenue Next Year18.24%
Revenue Next 2Y16.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.43%
OCF growth 3YN/A
OCF growth 5YN/A

VIVOSIM LABS INC / VIVS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of VIVOSIM LABS INC (VIVS) stock?

ChartMill assigns a fundamental rating of 4 / 10 to VIVS.


What is the valuation status of VIVOSIM LABS INC (VIVS) stock?

ChartMill assigns a valuation rating of 4 / 10 to VIVOSIM LABS INC (VIVS). This can be considered as Fairly Valued.


How profitable is VIVOSIM LABS INC (VIVS) stock?

VIVOSIM LABS INC (VIVS) has a profitability rating of 3 / 10.


What is the valuation of VIVOSIM LABS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for VIVOSIM LABS INC (VIVS) is 1.36 and the Price/Book (PB) ratio is 0.86.